Michael A Davies

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2862910/publications.pdf

Version: 2024-02-01

199 papers	27,241 citations	15001 68 h-index	7627 156 g-index
212 all docs	212 docs citations	212 times ranked	34938 citing authors

#	Article	IF	Citations
1	Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with antiâ€CTLA4 and antiâ€PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer, 2022, 128, 975-983.	2.0	12
2	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 2022, 162, 22-33.	1.3	28
3	Clinical Models to Define Response and Survival With Antiâ€“PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1068-1080.	0.8	43
4	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications, 2022, 13, 1970.	5.8	34
5	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clinical Cancer Research, 2022, 28, 1911-1924.	3.2	3
6	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro-Oncology, 2022, 24, 1613-1646.	0.6	39
7	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	1.6	7
8	LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. Journal of Clinical Investigation, 2022, 132, .	3.9	14
9	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell, 2022, 40, 509-523.e6.	7.7	115
10	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature, 2022, 606, 797-803.	13.7	54
11	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. Cancer Immunology Research, 2022, 10, 996-1012.	1.6	18
12	Multi-modal molecular programs regulate melanoma cell state. Nature Communications, 2022, 13, .	5.8	9
13	Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell, 2022, 185, 2591-2608.e30.	13.5	62
14	Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathologica, 2021, 141, 303-321.	3.9	30
15	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nature Communications, 2021, 12, 346.	5.8	107
16	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	9.4	118
17	iNOS Associates With Poor Survival in Melanoma: A Role for Nitric Oxide in the PI3K-AKT Pathway Stimulation and PTEN S-Nitrosylation. Frontiers in Oncology, 2021, 11, 631766.	1.3	10
18	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine, 2021, 27, 301-309.	15.2	218

#	Article	IF	Citations
19	Targeted Therapy Given after Antiâ€“PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer Immunology Research, 2021, 9, 554-567.	1.6	15
20	Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. Lancet Oncology, The, 2021, 22, 370-380.	5.1	57
21	Tilsotolimod with Ipilimumab Drives Tumor Responses in Antiâ€“PD-1 Refractory Melanoma. Cancer Discovery, 2021, 11, 1996-2013.	7.7	32
22	The efficacy of antiâ€programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. Cancer Medicine, 2021, 10, 2293-2299.	1.3	15
23	High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Scientific Reports, 2021, 11, 9043.	1.6	13
24	Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Annals of Surgical Oncology, 2021, 28, 3480-3489.	0.7	7
25	Efficacy and Safety of Trametinib in <scp>Non-V600 BRAF </scp> Mutant Melanoma: A Phase II Study. Oncologist, 2021, 26, 731-e1498.	1.9	20
26	Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. , 2021, 9, e002449.		16
27	Reâ€thinking therapeutic development for CNS metastatic disease. Experimental Dermatology, 2021, , .	1.4	1
28	Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. , 2021, 9, e002531.		24
29	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine, 2021, 27, 1432-1441.	15.2	216
30	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	5.8	58
31	High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiotherapy and Oncology, 2021, 162, 60-67.	0.3	45
32	Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases. Neuro-Oncology Advances, 2021, 3, vdaa177.	0.4	12
33	Identification of MicroRNAâ€“mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers, 2021, 13, 5301.	1.7	7
34	Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf -mutated melanoma. OncoImmunology, 2021, 10, 1992880.	2.1	7
35	Targeted therapy strategies for melanoma brain metastasis. Neuro-Oncology Advances, 2021, 3, v75-v85.	0.4	3
36	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science, 2021, 374, 1632-1640.	6.0	369

#	Article	IF	Citations
37	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Modern Pathology, 2020, 33, 496-513.	2.9	19
38	Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer, 2020, 126, 523-530.	2.0	43
39	Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma. British Journal of Cancer, 2020, 122, 789-800.	2.9	15
40	Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma. Cell Death and Disease, 2020, 11, 882.	2.7	10
41	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Annals of Oncology, 2020, 31, 1569-1579.	0.6	18
42	Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Medicine, 2020, 9, 8650-8661.	1.3	11
43	Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. Immunotherapy, 2020, 12, 1213-1219.	1.0	6
44	Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunology Research, 2020, 8, 1365-1380.	1.6	37
45	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell, 2020, 38, 829-843.e4.	7.7	40
46	Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition. Journal of Investigative Dermatology, 2020, 140, 2242-2252.e7.	0.3	23
47	Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma. Molecular Cancer Therapeutics, 2020, 19, 1719-1726.	1.9	22
48	Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discovery, 2020, 10, 1352-1373.	7.7	145
49	Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. , 2020, 8, e000289.		51
50	Is It Safe to Stop Antiâ€“PD-1 Immunotherapy in Patients With Metastatic Melanoma Who Achieve a Complete Response?. Journal of Clinical Oncology, 2020, 38, 1645-1647.	0.8	10
51	FOXD3 Regulates VISTA Expression in Melanoma. Cell Reports, 2020, 30, 510-524.e6.	2.9	42
52	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	13.7	1,421
53	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	0.8	23
54	Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions. Pigment Cell and Melanoma Research, 2020, 33, 527-541.	1.5	36

#	Article	IF	Citations
55	Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis. Molecular Oncology, 2020, 14, 1760-1778.	2.1	27
56	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nature Communications, 2020, 11, 1839.	5.8	15
57	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clinical Cancer Research, 2020, 26, 1886-1895.	3.2	42
58	EXTH-06. INTEGRATED MOLECULAR PROFILING REVEALS TARGETABLE MOLECULAR ABNORMALITIES SHARED ACROSS MULTIPLE HISTOLOGIES OF BRAIN METASTASIS. Neuro-Oncology, 2020, 22, ii87-ii88.	0.6	0
59	Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with antiâ€“PDâ€1 in patients with metastatic melanoma. Cancer, 2019, 125, 4193-4202.	2.0	9
60	Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3KÎ² Inhibition in PTEN Loss Melanoma. Clinical Cancer Research, 2019, 25, 6406-6416.	3.2	35
61	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	5.1	155
62	In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma. Molecular Cancer Therapeutics, 2019, 18, 1637-1648.	1.9	14
63	Regulation of PRMT5â€“MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17990-18000.	3.3	81
64	A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma. Clinical Cancer Research, 2019, 25, 6429-6442.	3.2	61
65	AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis. Molecular Cancer Research, 2019, 17, 1787-1800.	1.5	46
66	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. New England Journal of Medicine, 2019, 381, 626-636.	13.9	909
67	Modern Management of Central Nervous System Metastases in the Era of Targeted Therapy and Immune Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e59-e69.	1.8	8
68	Reply to A. Shinde et al. Journal of Clinical Oncology, 2019, 37, 1031-1032.	0.8	0
69	Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). Journal of Neuro-Oncology, 2019, 142, 499-509.	1.4	33
70	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discovery, 2019, 9, 628-645.	7.7	231
71	Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo. Cells, 2019, 8, 1487.	1.8	20
72	Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. , 2019, 7, 319.		164

#	Article	IF	Citations
73	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell and Melanoma Research, 2019, 32, 458-469.	1.5	31
74	Case Report: Sarcoidosis mimicking head and neck cancer progression. F1000Research, 2019, 8, 215.	0.8	2
75	In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2â€“CDK4/6 Targeting and mTORâ€“S6 Resistance Mechanisms. Cancer Discovery, 2018, 8, 568-581.	7.7	62
76	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clinical Cancer Research, 2018, 24, 3366-3376.	3.2	73
77	A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discovery, 2018, 8, 556-567.	7.7	55
78	Estrogen returns to the stage in melanoma. Pigment Cell and Melanoma Research, 2018, 31, 554-555.	1.5	4
79	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metabolism, 2018, 27, 977-987.e4.	7.2	398
80	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open, 2018, 3, e000283.	2.0	45
81	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2018, 19, 181-193.	5.1	233
82	Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncology, The, 2018, 19, 310-322.	5.1	486
83	Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications. Pigment Cell and Melanoma Research, 2018, 31, 11-30.	1.5	149
84	Gut microbiome modulates response to antiâ€“PD-1 immunotherapy in melanoma patients. Science, 2018, 359, 97-103.	6.0	3,126
85	Firstâ€inâ€human trial of the PI3KÎ²â€selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer, 2018, 124, 315-324.	2.0	29
86	Moving treatments earlier to move further forwards. Nature Reviews Clinical Oncology, 2018, 15, 75-76.	12.5	7
87	Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. Journal of Neuro-Oncology, 2018, 137, 67-75.	1.4	17
88	Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo. Molecular Cancer Therapeutics, 2018, 17, 84-95.	1.9	22
89	Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precision Oncology, 2018, 2018, 1-19.	1.5	19
90	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654.	15.2	592

#	Article	IF	Citations
91	Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clinical Cancer Research, 2018, 24, 4119-4125.	3.2	11
92	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clinical Cancer Research, 2018, 24, 4416-4428.	3.2	89
93	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of Oncology, 2018, 29, 1861-1868.	0.6	135
94	Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrowâ€“Resident Melanoma CTCs. Cancer Research, 2018, 78, 5349-5362.	0.4	36
95	ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Molecular Cancer Research, 2018, 16, 1724-1736.	1.5	74
96	Body-mass index and metastatic melanoma outcomes â€“ Authors' reply. Lancet Oncology, The, 2018, 19, e227-e228.	5.1	3
97	ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Research, 2018, 78, 5680-5693.	0.4	19
98	Sex as a predictor of response to cancer immunotherapy. Lancet Oncology, The, 2018, 19, e376.	5.1	8
99	Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease. Journal of Neuropathology and Experimental Neurology, 2018, 77, 628-635.	0.9	57
100	Profiles of brain metastases: Prioritization of therapeutic targets. International Journal of Cancer, 2018, 143, 3019-3026.	2.3	31
101	Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Molecular Cancer Therapeutics, 2017, 16, 516-528.	1.9	55
102	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, .	5.8	689
103	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell, 2017, 31, 225-239.	7.7	190
104	Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-ÎºB Pathway in Melanoma. Clinical Cancer Research, 2017, 23, 4831-4842.	3.2	33
105	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of Oncology, 2017, 28, 1631-1639.	0.6	549
106	Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. Cell Reports, 2017, 19, 875-889.	2.9	78
107	Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. Journal of Investigative Dermatology, 2017, 137, 1792-1795.	0.3	40
108	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. Cancer Discovery, 2017, 7, 832-851.	7.7	49

#	Article	IF	Citations
109	Clinicopathological features and clinical outcomes associated with TP53 and BRAF^N^{ona€}^V⁶⁰⁰ mutations in cutaneous melanoma patients. Cancer, 2017, 123, 1372-1381.	2.0	36
110	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. European Journal of Cancer, 2017, 82, 45-55.	1.3	160
111	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 863-873.	5.1	561
112	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	1.7	120
113	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		111
114	Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clinical Cancer Research, 2017, 23, 2093-2104.	3.2	48
115	Erythema nodosumâ€like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapyâ€"Report of 2 patients. Journal of Cutaneous Pathology, 2017, 44, 1080-1086.	0.7	48
116	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiotherapy and Oncology, 2017, 125, 80-88.	0.3	58
117	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications, 2017, 8, 607.	5.8	109
118	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. OncoImmunology, 2017, 6, e1361097.	2.1	50
119	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports, 2017, 21, 1936-1952.	2.9	72
120	Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene. Molecular Cell, 2017, 68, 731-744.e9.	4.5	90
121	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 2017, 21, 1953-1967.	2.9	117
122	Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. JAMA Dermatology, 2017, 153, 228.	2.0	10
123	Primary medical therapy for BRAFV600E-mutant melanoma brain metastasesâ€"is this good enough? â€" Authors' reply. Lancet Oncology, The, 2017, 18, e509.	5.1	3
124	COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600â€"mutant (mut) melanoma brain metastases (MBM).. Journal of Clinical Oncology, 2017, 35, 9506-9506.	0.8	10
125	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. Journal of Clinical Investigation, 2016, 126, 1834-1856.	3.9	219
126	Nextâ€generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma. Journal of Pathology, 2016, 240, 84-95.	2.1	63

#	Article	IF	Citations
127	MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRASÂMelanoma. Journal of Investigative Dermatology, 2016, 136, 453-463.	0.3	13
128	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitorâ€"Refractory Metastatic Melanoma. JAMA Oncology, 2016, 2, 1056.	3.4	41
129	An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. Cancer Research, 2016, 76, 5455-5466.	0.4	24
130	The state of melanoma: challenges and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 404-416.	1.5	77
131	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell and Melanoma Research, 2016, 29, 627-642.	1.5	102
132	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncology, The, 2016, 17, 1743-1754.	5.1	266
133	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine, 2016, 14, 168.	2.3	106
134	Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Scientific Reports, 2016, 6, 19649.	1.6	15
135	How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 787-792.	2.3	4
136	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	7.7	785
137	Loss of PTEN Promotes Resistance to T Cellâ€"Mediated Immunotherapy. Cancer Discovery, 2016, 6, 202-216.	7.7	1,158
138	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology, 2016, 5, e1136044.	2.1	55
139	Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clinical Cancer Research, 2016, 22, 3016-3024.	3.2	39
140	Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents. Oncogene, 2016, 35, 1632-1642.	2.6	19
141	IMCT-07THERAPEUTIC OUTCOMES OF INTRATHECAL INTERLEUKIN-2 IN METASTATIC MELANOMA PATIENTS WITH LEPTOMENINGEAL DISEASE (LMD). Neuro-Oncology, 2015, 17, v108.3-v108.	0.6	5
142	Role and complexity of nextâ€generation sequencing in melanoma. Cancer Cytopathology, 2015, 123, 329-330.	1.4	0
143	Converting biology into clinical benefit: lessons learned from BRAF inhibitors. Melanoma Management, 2015, 2, 241-254.	0.1	10
144	<scp>RAC</scp>1 P29S regulates <scp>PD</scp>â€L1 expression in melanoma. Pigment Cell and Melanoma Research, 2015, 28, 590-598.	1.5	69

#	Article	IF	Citations
145	Use of clinical nextâ€generation sequencing to identify melanomas harboring <scp>SMARCB1</scp> mutations. Journal of Cutaneous Pathology, 2015, 42, 308-317.	0.7	11
146	AKT1 Activation Promotes Development of Melanoma Metastases. Cell Reports, 2015, 13, 898-905.	2.9	124
147	Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clinical Chemistry, 2015, 61, 544-553.	1.5	85
148	mTORC1 Activation Blocks BrafV600E-Induced Growth Arrest but Is Insufficient for Melanoma Formation. Cancer Cell, 2015, 27, 41-56.	7.7	106
149	PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. Cancer Research, 2015, 75, 1399-1412.	0.4	50
150	Hotspot Mutation Panel Testing Reveals Clonal Evolution in a Study of 265 Paired Primary and Metastatic Tumors. Clinical Cancer Research, 2015, 21, 2644-2651.	3.2	70
151	ErbB3â€“ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Research, 2015, 75, 3554-3567.	0.4	18
152	BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunology Research, 2015, 3, 602-609.	1.6	133
153	A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. Journal of the National Cancer Institute, 2015, 107, .	3.0	168
154	BRAFin early stage melanoma: rationale for testing and treatment?. British Journal of Dermatology, 2015, 173, 9-10.	1.4	0
155	Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. Cancer Immunology Research, 2015, 3, 1201-1206.	1.6	29
156	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Human Pathology, 2015, 46, 1101-1110.	1.1	43
157	SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex. Cancer Research, 2015, 75, 5211-5218.	0.4	28
158	Development of a robust classifier for quality control of reverse-phase protein arrays. Bioinformatics, 2015, 31, 912-918.	1.8	43
159	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. Journal of Investigative Dermatology, 2015, 135, 508-515.	0.3	138
160	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1Î± and Oxidative Phosphorylation in Melanoma. Cancer Research, 2014, 74, 7037-7047.	0.4	161
161	Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor. Cancer Research, 2014, 74, 4122-4132.	0.4	45
162	Finding the Right Balance of BRAF Inhibition in Melanoma. Cancer Discovery, 2014, 4, 510-512.	7.7	3

#	Article	IF	Citations
163	Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin. Journal of Investigative Dermatology, 2014, 134, 452-460.	0.3	20
164	Emerging insights into resistance to BRAF inhibitors in melanoma. Biochemical Pharmacology, 2014, 87, 381-389.	2.0	70
165	Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target. Clinical Cancer Research, 2014, 20, 5537-5546.	3.2	169
166	Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations. Clinical Cancer Research, 2014, 20, 5527-5536.	3.2	145
167	Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma. Hematology/Oncology Clinics of North America, 2014, 28, 523-536.	0.9	23
168	Targeted therapy for melanoma: rational combinatorial approaches. Oncogene, 2014, 33, 1-9.	2.6	85
169	Genotyping of cutaneous melanoma. Chinese Clinical Oncology, 2014, 3, 27.	0.4	17
170	Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer, 2013, 119, 3821-3829.	2.0	87
171	Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma. Clinical Cancer Research, 2013, 19, 5310-5319.	3.2	78
172	BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. Clinical Cancer Research, 2013, 19, 393-403.	3.2	336
173	Targeted Therapy for Brain Metastases. Advances in Pharmacology, 2012, 65, 109-142.	1.2	11
174	The Role of the PI3K-AKT Pathway in Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 142-147.	1.0	197
175	Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. Clinical Cancer Research, 2012, 18, 5329-5340.	3.2	266
176	Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma. Clinical Cancer Research, 2012, 18, 1120-1128.	3.2	57
177	Role and therapeutic potential of PI3Kâ€mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell and Melanoma Research, 2012, 25, 248-258.	1.5	98
178	A Phase I Multi-Institutional Study of Systemic Sorafenib in Conjunction with Regional Melphalan for In-Transit Melanoma of the Extremity. Annals of Surgical Oncology, 2012, 19, 3896-3905.	0.7	22
179	Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. Clinical Cancer Research, 2012, 18, 6758-6770.	3.2	345
180	New Strategies in Melanoma: Molecular Testing in Advanced Disease. Clinical Cancer Research, 2012, 18, 1195-1200.	3.2	61

#	Article	IF	Citations
181	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2012, 13, 1087-1095.	5.1	841
182	A Landscape of Driver Mutations in Melanoma. Cell, 2012, 150, 251-263.	13.5	2,247
183	NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer, 2012, 118, 4014-4023.	2.0	589
184	Targeted Therapy for Melanoma: A Primer. Surgical Oncology Clinics of North America, 2011, 20, 165-180.	0.6	25
185	Regulation, Role, and Targeting of Akt in Cancer. Journal of Clinical Oncology, 2011, 29, 4715-4717.	0.8	48
186	Prognostic factors for survival in melanoma patients with brain metastases. Cancer, 2011, 117, 1687-1696.	2.0	433
187	Analysis of the genome to personalize therapy for melanoma. Oncogene, 2010, 29, 5545-5555.	2.6	125
188	Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells. Cancer Research, 2010, 70, 8736-8747.	0.4	222
189	Phosphatidylinositol-3-Kinase as a Therapeutic Target in Melanoma. Clinical Cancer Research, 2009, 15, 3029-3036.	3.2	59
190	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clinical Cancer Research, 2009, 15, 7538-7546.	3.2	221
191	A novel AKT3 mutation in melanoma tumours and cell lines. British Journal of Cancer, 2008, 99, 1265-1268.	2.9	237
192	Point mutations of protein kinases and individualised cancer therapy. Expert Opinion on Pharmacotherapy, 2006, 7, 2243-2261.	0.9	27
193	Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene, 2002, 21, 2357-2364.	2.6	21
194	Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene, 2001, 20, 6669-6678.	2.6	107
195	Differential Effects of Phosphatidylinositol-3/Akt-Kinase Inhibition on Apoptotic Sensitization to Cytokines in LNCaP and PC-3 Prostate Cancer Cells. Journal of Interferon and Cytokine Research, 2001, 21, 313-322.	0.5	21
196	MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene, 2000, 19, 5406-5412.	2.6	94
197	The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene, 1999, 18, 7034-7045.	2.6	288
198	Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Research, 1999, 59, 2551-6.	0.4	205

#	Article	IF	Citations
199	Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Research, 1998, 58, 5285-90.	0.4	160